

EpiHealth declares bankruptcy – Recalls Cloderm[®] (clocortolone pivalate) and Minolira[™] (minocycline)

- On April 24, 2024, [EpiHealth announced](#) a voluntary consumer-level recall of some lots of [Cloderm \(clocortolone pivalate\)](#) topical cream and [Minolira \(minocycline\)](#) extended-release tablets as a result of the company declaring bankruptcy in July 2023.
- The reason for the recall is because EpiHealth has discontinued any quality activities related to these drugs and will not be able to support or guarantee that these drugs will meet all intended specifications through their labeled shelf life.

Product Description	NDC number	Lot number (Exp Date)
Cloderm (clocortolone pivalate) 0.1% cream, 45 g tube	71403-0804-45	SFDC (5/31/2024); TFBW (5/31/2025)
Minolira (minocycline) ER 105 mg tablets, 30 count bottle	71403-0101-30	T2300765 (11/30/2025); T2201702A (2/28/2025); T2201699 (2/28/2025); T2201698 (2/28/2025)
Minolira (minocycline) ER 135 mg tablets, 30 count bottle	71403-102-30	T2201700 (2/28/2025); T2201701 (2/28/2025)

- Cloderm is a topical steroid indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
- Minolira is indicated to treat the inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.
- To date EpiHealth has not received any reports of adverse events related to this recall.
- Anyone with an existing inventory of the product being recalled should examine the product, quarantine any of the recalled lots immediately, and properly dispose of it.
- Contact EpiHealth by phone at **1-888-671-8858** or by email at ppsi7150@sedgwick.com for questions regarding this recall.